肥厚型心肌病的诊断及治疗研究进展
Research Progress in the Diagnosis and Treatment of HCM
DOI: 10.12677/ACM.2023.1392054, PDF,   
作者: 唐雍淇, 迪丽努尔·买买提依明*：新疆医科大学第一附属医院综合心脏内科，新疆 乌鲁木齐；娜孜拉·努尔兰：新疆医科大学第七附属医院心血管内科，新疆 乌鲁木齐
关键词: 肥厚型心肌病；诊断；预后；治疗；Hypertrophic Cardiomyopathy； Diagnosis； Prognosis； Treatment
摘要: 肥厚型心肌病(Hypertrophic cardiomyopathy, HCM)是一种常见的世界性遗传性心肌病，其主要的原因是肌小节蛋白编码基因(或肌小节蛋白相关基因)变异，导致左心室心肌肥厚、纤维化、收缩性增强和顺应性降低。HCM是最常见的遗传性单基因心脏疾病，全球平均约有0.20% (1/500)的人口深受HCM的影响。随着医疗技术的发展，对HCM的诊断方法也越来越多，新的治疗手段也随之出现，但现有的治疗方案仍无法根治HCM，仅仅以减轻症状为主。本文结合最新相关研究，对HCM的诊断、预后及治疗进行系统阐述，以增进对疾病的认识。
Abstract: Hypertrophic cardiomyopathy (HCM) is a common worldwide inherited cardiomyopathy caused by mutations in the myodon-coding gene (or myodonin-related gene) that results in left ventricular myocardial hypertrophy, fibrosis, increased contractility, and decreased compliance. HCM is the most common inherited monogenic heart disease, affecting an average of about 0.20% (1 in 500) of the global population. With the development of medical technology, there are more and more diag-nostic methods for HCM, and new treatment methods have emerged, but the existing treatment op-tions still cannot cure HCM, only to reduce symptoms. This article systematically elaborates the di-agnosis, prognosis and treatment of HCM based on the latest relevant studies to improve the under-standing of disease awareness and research progress.
文章引用：唐雍淇, 娜孜拉·努尔兰, 迪丽努尔·买买提依明. 肥厚型心肌病的诊断及治疗研究进展[J]. 临床医学进展, 2023, 13(9): 14695-14700. https://doi.org/10.12677/ACM.2023.1392054

参考文献

[1] Teare, D. (1958) Asymmetrical Hypertrophy of the Heart in Young Adults. British Heart Journal, 20, 1-8. [Google Scholar] [CrossRef] [PubMed]
[2] Maron, B., Rowin, E., Casey, S., et al. (2015) Hypertrophic Cardiomyopa-thy in Adulthood Associated with Low Cardiovascular Mortality with Contemporary Management Strategies. Journal of the American College of Cardiology, 65, 1915-1928. [Google Scholar] [CrossRef] [PubMed]
[3] Spudich, J. (2019) Three Perspectives on the Molecular Basis of Hypercontractility Caused by Hypertrophic Cardiomyopathy Muta-tions. Pflugers Archiv: European Journal of Physiology, 471, 701-717. [Google Scholar] [CrossRef] [PubMed]
[4] Jacobson, J. (2019) Arrhythmia Evaluation and Management. Cardiology Clinics, 37, 55-62. [Google Scholar] [CrossRef] [PubMed]
[5] Maron, B. (2018) Clinical Course and Management of Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 379, 655-668. [Google Scholar] [CrossRef] 
[6] 邹玉宝, 宋雷. 中国成人肥厚型心肌病诊断与治疗指南解读[J]. 中国循环杂志, 2018, 33(S2): 68-73.
[7] 戴霞飞, 李小平. 肥厚型心肌病的遗传学进展[J]. 医学综述, 2018, 24(20): 3953-3958.
[8] Elliott, P. and Mckenna, W. (2004) Hypertrophic Cardiomyopathy. The Lancet (London, Eng-land), 363, 1881-1891. [Google Scholar] [CrossRef] 
[9] Williams, L. and Frenneaux, M. (2007) Syncope in Hyper-trophic Cardiomyopathy: Mechanisms and Consequences for Treatment. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 9, 817-822.
[10] Nagueh, S., Phelan, D., Abraham, T., et al. (2022) Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardi-ology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography, 35, 533-569. [Google Scholar] [CrossRef] [PubMed]
[11] Caselli, S., Maron, M., Urbano-Moral, J., et al. (2014) Differentiating Left Ventricular Hypertrophy in Athletes from That in Patients with Hypertrophic Cardiomyopathy. The American Journal of Cardiology, 114, 1383-1389. [Google Scholar] [CrossRef] [PubMed]
[12] 邵虹, 马志玲, 刘丽文. 肥厚型心肌病心电图特征分析[J]. 临床心电学杂志, 2015, 24(3): 177-180.
[13] Mcleod, C., Ackerman, M., Nishimura, R., et al. (2009) Outcome of Pa-tients with Hypertrophic Cardiomyopathy and a Normal Electrocardiogram. Journal of the American College of Cardiol-ogy, 54, 229-233. [Google Scholar] [CrossRef] [PubMed]
[14] Maron, B. and Maron, M. (2013) Hypertrophic Cardiomyopathy. The Lancet (London, England), 381, 242-255. [Google Scholar] [CrossRef] 
[15] Luckie, M. and Khattar, R. (2008) Systolic Anterior Motion of the Mitral Valve—Beyond Hypertrophic Cardiomyopathy. Heart (British Cardiac Society), 94, 1383-1385. [Google Scholar] [CrossRef] [PubMed]
[16] Maron, M., Olivotto, I., Betocchi, S., et al. (2003) Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 348, 295-303. [Google Scholar] [CrossRef] 
[17] 王怀根, 卢群, 马爱群. 《中国成人肥厚型心肌病诊断与治疗指南2023》解读[J]. 疑难病杂志, 2023, 22(6): 561-565.
[18] 徐萍萍. 实时超声心动图三维斑点追踪技术对肥厚型心肌病患者左室整体收缩功能及收缩同步性的评价应用探讨[J]. 中外医学研究, 2019, 17(21): 54-56.
[19] 彭源, 杨军, 谢明星, 等. 三维超声成像评价肥厚型心肌病左室节段收缩同步性与整体功能的初步研究[J]. 华中科技大学学报(医学版), 2016, 45(5): 523-528.
[20] Rajtar-Salwa, R., Petkow-Dimitrow, P. and Miszalski-Jamka, T. (2016) Role of Cardiac Magnetic Resonance in Differentiating between Acute Coronary Syndrome and Apical Hypertrophic Cardiomyopathy. Advances in Interventional Cardiology, 12, 380-382. [Google Scholar] [CrossRef] [PubMed]
[21] Maron, M. and Maron, B. (2015) Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy. Circulation, 132, 292-298. [Google Scholar] [CrossRef] 
[22] Chan, R., Maron, B., Olivotto, I., et al. (2014) Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 130, 484-495. [Google Scholar] [CrossRef] 
[23] 李硕, 李成华, 靳温. 肌酸激酶-同工酶亚型的检测及其在心肌损伤中的应用[J]. 心血管康复医学杂志, 2020, 29(2): 183-186.
[24] 王付镇, 王德杰, 刘丹. 彩色多普勒心脏超声联合血清cTnI、CK-MB、NT-proBNP检测在老年肥厚型梗阻性心肌病诊断中的应用效果[J]. 影像研究与医学应用, 2022, 6(15): 13-15.
[25] 钟文津, 景香香, 唐海霞, 等. 彩色多普勒心脏超声联合血清cTnI、CK-MB、NT-proBNP检测在老年肥厚型梗阻性心肌病诊断中的应用[J]. 中国老年学杂志, 2021, 41(16): 3396-3399.
[26] Sherrid, M. (2016) Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Current Cardiology Reviews, 12, 52-65. [Google Scholar] [CrossRef] 
[27] Rowin, E., Hausvater, A., Link, M., et al. (2017) Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 136, 2420-2436. [Google Scholar] [CrossRef] 
[28] Baker, J. (2010) The Selectivity of beta-Adrenoceptor Agonists at Human beta1-, beta2- and beta3-Adrenoceptors. British Journal of Phar-macology, 160, 1048-1061. [Google Scholar] [CrossRef] [PubMed]
[29] Elliott, P., Anastasakis, A., Borger, M., et al. (2014) 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35, 2733-2779. [Google Scholar] [CrossRef] [PubMed]
[30] Sherrid, M., Shetty, A., Winson, G., et al. (2013) Treatment of Ob-structive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy with β-Blockade or Ve-rapamil. Circulation Heart Failure, 6, 694-702. [Google Scholar] [CrossRef] 
[31] Smedira, N., Lytle, B., Lever, H., et al. (2008) Current Effectiveness and Risks of Isolated Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. The Annals of Thoracic Surgery, 85, 127-133. [Google Scholar] [CrossRef] [PubMed]
[32] Olivotto, I., Oreziak, A., Barriales-Villa, R., et al. (2020) Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): A Ran-domised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet (London, England), 396, 759-769. [Google Scholar] [CrossRef] 
[33] 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国分子心脏病学杂志, 2023, 23(1): 5115-5149. [Google Scholar] [CrossRef] 
[34] Maron, B. and Nishimura, R. (2014) Surgical Septal Myectomy versus Alcohol Septal Ablation: Assessing the Status of the Controversy in 2014. Circulation, 130, 1617-1624. [Google Scholar] [CrossRef] 

为你推荐